Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12306795 | 0.87 | MEN1 (0.35) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL2627751 | 0.87 | MEN1 (0.35) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL11378565 | 0.86 | MEN1 (0.34) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL9180802 | 0.86 | MEN1 (0.34) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL12306794 | 0.85 | MEN1 (0.37) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL10000055 | 0.83 | NFE2L2 (0.44) | MEN1KMT2A | |
| SCHEMBL14493463 | 0.83 | MEN1 (0.33) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL16001798 | 0.82 | MEN1 (0.35) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL16001812 | 0.82 | MEN1 (0.35) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL10565035 | 0.82 | KMT2A (0.45) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106036-B2 | Pharmaceutical compositions-4 | HARBOR BIOSCIENCES, INC. (US) | 2012-01-31 | — | — | US | disclosed |
| US-7947846-B2 | 15-OXA-steroid compounds | HARBOR BIOSCIENCES, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20100222313-A1 | PHARMACEUTICAL COMPOSITIONS-4 | BIOVIE INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100222425-A1 | COMPOSITIONS AND TREATMENT METHODS-2 | BIOVIE INC. | 2010-09-02 | — | — | US | disclosed |
| US-7723532-B2 | Pharmaceutical compositions 3 | HARBOR BIOSCIENCES, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090215737-A1 | Pharmaceutical Compositions - 2 | BIOVIE INC. | 2009-08-27 | — | — | US | disclosed |
| US-7524835-B2 | Tetrol steroids and esters | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-20080176824-A1 | Pharmaceutical Compositions 3 | BIOVIE INC. | 2008-07-24 | — | — | US | disclosed |
| US-7396827-B2 | Pharmaceutical compositions and treatment methods | HOLLIS-EDEN PHARMACEUTICALS, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20080045490-A1 | Pharmaceutical Compositions | BIOVIE INC. | 2008-02-21 | — | — | US | disclosed |
| US-20070275936-A1 | Formulations and Treatment Methods | BIOVIE INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070129282-A1 | Pharmaceutical treatments and compositions | BIOVIE INC. | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045490-A1 | Pharmaceutical Compositions | HSD3B1, HSD17B3, HSD17B1 | MEN1 1735/4885KMT2A 2724/4885KDM4C 1943/4885 |
| US-20090215737-A1 | Pharmaceutical Compositions - 2 | HSD3B2, HSD3B1, HSD17B2 | MEN1 2221/4885KMT2A 1951/4885KDM4C 2717/4885 |
| US-20070129282-A1 | Pharmaceutical treatments and compositions | HSD3B1, HSD3B2, HSD17B1 | MEN1 2235/4885KMT2A 2790/4885KDM4C 2173/4885 |
| US-20100222425-A1 | COMPOSITIONS AND TREATMENT METHODS-2 | MPL, THPO, HSD3B2 | MEN1 1314/4885KMT2A 3129/4885KDM4C 3991/4885 |
| US-20100222313-A1 | PHARMACEUTICAL COMPOSITIONS-4 | HSD3B1, HSD3B2, HSD17B7 | MEN1 2281/4885KMT2A 2863/4885KDM4C 900/4885 |
| US-20080176824-A1 | Pharmaceutical Compositions 3 | HSD3B1, HSD17B3, HSD3B2 | MEN1 2267/4885KMT2A 3418/4885KDM4C 2417/4885 |
| US-20070275936-A1 | Formulations and Treatment Methods | HSD3B1, HSD17B1, HSD17B3 | MEN1 2126/4885KMT2A 2432/4885KDM4C 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.